Press Releases

TheraVet élargit significativement sa gamme BIOCERA-VET® grâce à d’importants accords de distribution et de recherche

November 23, 2021

 

TheraVet (code ISIN : BE0974387194 — mnémonique : ALVET), société de biotechnologie pionnière dans le traitement des maladies ostéo-articulaires des animaux de compagnie, annonce aujourd’hui un partenariat enrichissant significativement le portefeuille de substituts osseux de TheraVet avec (i) deux nouvelles lignes exclusives et complémentaires de substituts osseux, (ii) des endoprothèses osseuses bio-imprimées en 3D pour des greffes osseuses personnalisées, et (iii) le développement de produits propriétaires de nouvelle génération. ...

 

Lire plus

 

PREVIOUS PRESS RELEASES

 

 

 

TheraVet announces positive safety and efficacy results for BIOCERA-VET® in canine osteosarcoma

November 15, 2021

 

TheraVet (ISIN: BE0974387194 - ticker: ALVET), a pioneering company in the management of osteoarticular diseases in pets, today announces the positive safety and efficacy results for BIOCERA-VET® used in cementoplasty as palliative treatment for canine osteosarcoma. ...

 

Read more

Lire plus

 

 

TheraVet expands its bone substitutes product line

November 03, 2021

 

TheraVet (ISIN: BE0974387194 - ticker: ALVET), a pioneering company in the management of osteoarticular diseases in pets, announces today the renewal and extension of the exclusive worldwide licence with Graftys and the addition of a highly injectable bone substitute to its portfolio. ...

 

Read more

Lire plus

Less meer

 

 

First patients treated with BIOCERA-VET® Bone Surgery in the United States of America

October 26, 2021

 

TheraVet (ISIN: BE0974387194 - ticker: ALVET), a pioneering company in the management of osteoarticular diseases in companion animals, announces today the first two dog patients treated with BIOCERA-VET® Bone Surgery in United Stated of America. ...

 

Read more

 

__________

 

 

Commercial Launch of BIOCERA-VET® in France and The Netherlands

October 21, 2021

 

Read more

 

 

 

TheraVet apporte des précisions sur ses relations avec la société Graftys

October 08, 2021

 

 

Read more

__________

 

TheraVet announces the launch of the pivotal European multicentric clinical study of VISCO-VET in canine osteoarthritis

September 10, 2021

 

Read more

Lire plus

Lees meer

 


TheraVet announces positive safety and efficacy results for VISCO-VET in canine osteoarthritis

September 8, 2021

 

Read more

Lire plus

Lees meer

 

__________

 

TheraVet provides its half-year operational update of 2021

July 7, 2021

 

Read more

Lire plus

 

__________

 

TheraVet extends the use of BIOCERA-VET to new curative approach of osteosarcoma in dogs

July 2, 2021

 

Read more

Lire plus

 

__________

 

TheraVet announces its 2021 financial calendar

June 30, 2021

 

Read more

 

__________

 

TheraVet: Successful IPO on Euronext Growth® Paris and Brussels

June 11, 2021

 

Read more (To view TheraVet's opening bell ceremony, click here.)

 

__________

 

TheraVet: Initial Public Offering on Euronext Growth® Brussels and Paris

May 26, 2021

 

Read more

 


BIOCERA-VET: a promising alternative to autologous bone graft in canine arthrodesis

April 27, 2021

 

Read more

 

__________

 

TheraVet announces the commercial launch of BIOCERA-VET

April 01, 2021

 

Read more

 

__________

 

Positive results of a single intra-articular injection of VISCO-VET in canine osteoarthritis

March 04, 2021

 

Read more

 

__________

 

Positive results in canine cranial cruciate ligament deficiency

January 26, 2021

 

Read more

__________

 

TheraVet raises 4 M€  to accelerate the development of its two veterinary products

December 10, 2020

 

Read more

 

__________

 

TheraVet launches a prospective multicentric clinical trial in canine osteosarcoma

November 17, 2020

 

Read more

This website uses cookies The website of TheraVet SA uses functional cookies. In case of analysing our traffic or advertising, we also place cookies that share information about your use of our site with our analytics partners, our social media and advertising partners, who may combine it with other information that you’ve provided to them or that they’ve collected from your use of their services.
Show details Hide details
Allow selection Allow all cookies